当前位置： SCI文献检索 > Health and Quality of Life Outcomes期刊下所有文献 > Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom.

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom.

Abstract：

BACKGROUND:To date, reliable and comprehensive health-related quality of life data for patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) have not been collected in clinical trials of the disease, and no utility studies have been published. The purpose of this study was to define and validate health states experienced by adults with relapsed/refractory B-precursor ALL, and to assign utility values to these health states using time-trade off methodology. METHODS:This study was conducted in the UK in three phases. In the first phase, five health state descriptions were developed based on a recent clinical trial. The second phase validated the health state descriptions with clinicians and patients with experience of relapsed/refractory B-precursor ALL. The third phase involved prospective health state valuation using time-trade off methodology in a sample of the general public. The study was approved by the UK National Health Service Research Ethics Committee. RESULTS:In total, 123 participants were recruited and included in the final analysis; all participants gave written, informed consent. Complete remission was the most preferred health state (mean utility [SEM], 0.86 [0.01]), followed by complete remission with partial hematological recovery (with minimal risk of bleeding or developing infection) (0.75 [0.02]); aplastic bone marrow (0.59 [0.02]); partial remission (0.50 [0.03]); and progressive disease (0.30 [0.04]). CONCLUSIONS:This is the first study to report utility values for health states associated with relapsed/refractory B-precursor ALL. It was designed and conducted to align with NICE guidance on alternative methods for generating health state utility values when EQ-5D data are either unavailable or inappropriate. These utilities can be applied in future cost-effectiveness analyses of treatment for relapsed/refractory B-precursor ALL.

journal_name

Health Qual Life Outcomes

journal_title

Health and quality of life outcomes

authors

Aristides M,Barlev A,Barber B,Gijsen M,Quinn C

doi

10.1186/s12955-015-0377-3

subject

Has Abstract

pub_date

2015-11-16 00:00:00

pages

181

issn

1477-7525

pii

10.1186/s12955-015-0377-3

journal_volume

pub_type

杂志文章

在线工具

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom.